Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy.
AHNAK2
bladder cancer
prognosis
radical cystectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
07
03
2021
revised:
01
04
2021
accepted:
06
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Data regarding expression levels of AHNAK2 in bladder cancer (BCa) have been very scarce. We retrospectively reviewed clinical data including clinicopathological features in 120 patients who underwent radical cystectomy (RC) for BCa. The expression levels of AHNAK2 in the specimens obtained by RC were classified as low expression (LE) or high expression (HE) by immunohistochemical staining. Statistical analyses were performed to compare associations between the two AHNAK2 expression patterns and the prognoses in terms of recurrence-free survival (RFS) and cancer-specific survival (CSS). A Kaplan-Meier analysis showed that patients with HE had a significantly worse RFS and CSS than those with LE (hazard ratio [HR]: 1.78, 95% confidence interval [CI]: 1.02-2.98,
Identifiants
pubmed: 33918555
pii: cancers13081748
doi: 10.3390/cancers13081748
pmc: PMC8069489
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI)
ID : JP18K09206
Références
Cancer Genomics Proteomics. 2010 Jul-Aug;7(4):181-9
pubmed: 20656984
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Mol Cells. 2013 Mar;35(3):226-34
pubmed: 23456298
EBioMedicine. 2019 Sep;47:208-220
pubmed: 31420300
PLoS One. 2014 May 02;9(5):e91548
pubmed: 24785714
Cancer Control. 2015 Apr;22(2):211-9
pubmed: 26068767
Cancer Lett. 2020 Jan 1;468:72-81
pubmed: 31605776
Cytokine Growth Factor Rev. 2021 Feb;57:93-111
pubmed: 32475760
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820957006
pubmed: 33000678
Br J Cancer. 2019 Jul;121(1):65-75
pubmed: 31123345
Eur Urol. 2015 Feb;67(2):241-9
pubmed: 25257030
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Sci Rep. 2020 Dec 14;10(1):21873
pubmed: 33318517
World J Urol. 2006 Aug;24(3):296-304
pubmed: 16518661
J Cell Biochem. 2015 Aug;116(8):1522-31
pubmed: 25560297
BJU Int. 2013 Jul;112(2):E51-8
pubmed: 23795798
Urology. 2007 Sep;70(3):602-7
pubmed: 17688917
Front Genet. 2019 Nov 22;10:1187
pubmed: 31824575
Int J Mol Sci. 2020 Jun 03;21(11):
pubmed: 32503307
Biomed Res. 2014;35(3):201-6
pubmed: 24942859
Cancer Biother Radiopharm. 2019 Dec;34(10):626-633
pubmed: 31621397
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4053-8
pubmed: 15007166
Nat Commun. 2018 Aug 29;9(1):3503
pubmed: 30158554
Theranostics. 2017 Feb 27;7(5):1100-1113
pubmed: 28435451
Urol Oncol. 2021 Mar;39(3):196.e1-196.e7
pubmed: 33160845
Am J Pathol. 2019 Mar;189(3):619-631
pubmed: 30770125
Oncotarget. 2017 May 9;8(19):31775-31784
pubmed: 28423668
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
BJU Int. 2012 Mar;109(6):846-54
pubmed: 21812902
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
Aging (Albany NY). 2020 Sep 23;12(18):18163-18180
pubmed: 32966238
Biomed Res Int. 2020 Aug 20;2020:8571932
pubmed: 32904605
Onco Targets Ther. 2020 Dec 16;13:12893-12903
pubmed: 33363388